CollPlant reveals it is developing bioprinted breast implants

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Israeli bioprinting company CollPlant has just announced that it has successfully produced the first 3D bioprinted implant prototypes for breast tissue regeneration. The bioprinted breast implants, which have been in development for some time, could offer a safer, patient-specific alternative for breast implantations down the line.

CollPlant’s development of breast tissue implants has remained under wraps until today, but we now have the first details on how the bioprinting initiative is going. According to the Rehovot-based biotech company, the implants are primarily comprised of its proprietary type I recombinant human collagen material—rhCollagen—and are designed to be loaded with patient-derived fat cells.

CollPlant breast implant bioprinted
CollPlant’s rhCollagen

The idea behind the tissue regeneration implants is that the fat cells will grow and thrive when they are embedded in the bioprinted scaffold. Once the breast implant has been placed inside the patient’s body, the scaffold is designed to degrade, resulting in a natural breast implant that is made up entirely of the patient’s own tissue cells.

“The implants we are developing leverage our 3D bioprinting technology and the unique properties of our recombinant human collagen, that has an excellent safety profile,” explained CollPlant CEO, Yehiel Tal. “We believe that our technology can eliminate the high risk for adverse events associated with permanent breast implants and provide a revolutionary alternative. This technology is already raising interest from leading companies in this segment.”

Presently, breast implant surgery mainly relies on implanting a prosthesis made of silicone gel or other artificial fillers into the patient’s chest. This approach, though popular, comes with its fair share of rejection risks. An alternative method, lipofilling, injects tissues derived from the patient to reconstruct breasts, but it also presents its own limitations in terms of size and shape.

The ability to bioprint a breast implant made from the patient’s own cells could therefore be a game-changer for breast cancer reconstruction and breast enhancement surgery, as it would eliminate the risk of rejection and could be tailored to the patient’s needs or wishes.

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.